Compare Johnson & Johnson (JNJ) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Wendys Co — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Wendys Co trades at $6.23 (market cap $1.19B). The key difference: Johnson & Johnson is far larger — about 519.4× Wendys Co's market cap, and Wendys Co pays the higher dividend (4.49%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Wendys Co for 77 Days on average.
| JNJ | WEN | |
|---|---|---|
Market Cap | $618.09B | $1.19B |
Volume | 6,050,983 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $9.33 |
52-Week Low | $186.00 | $6.10 |
Typical Hold Time | 129 Days | 77 Days |
Enterprise Value | $646.37B | $4.92B |
Dividend Yield | 2.09% | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Wendy's (WEN) trades at $6.22, up 1.8% today but remains in a bearish technical trend with declining fundamentals. Revenue has stagnated around $2.2B, while net income fell to $165M in 2025, with a projected drop to $126M in 2026. The stock appears undervalued with a P/E of 9.45 and P/S of 0.54, but faces headwinds from a major franchisee bankruptcy and six consecutive quarters of same-store sales declines.
The outlook is cautious due to operational challenges and high debt, though the low valuation and consistent dividend offer some support. Analyst consensus is a 'Hold' with a $7.58 price target, reflecting skepticism about near-term recovery. Key risks include competitive pressure, execution missteps, and macroeconomic strain on consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
